Mainz Biomed B.V.
Mainz Biomed B.V. (MYNZ) Stock Overview
Explore Mainz Biomed B.V.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7.6M
P/E Ratio
-0.09
EPS (TTM)
$-22.36
ROE
-22.70%
MYNZ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Mainz Biomed B.V. (MYNZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 63.31, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.21.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.09 and a market capitalization of 7.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Guido Baechler
19
Robert Koch Strasse 50, Mainz
2021